The Campath®-1H Sensitivity (CD52) test contains 1 test with 3 biomarkers.
Campath® (Alemtuzumab) is indicated for the treatment of patients with CD52 positive chronic lymphocytic leukemia.
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Campath1H Sensitivity CD52